Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches.
2017-12-08 07:46來源：原版作者：Krebs MG
Epithelial circulating tumor cells (CTCs) are detectable in patients with non-small cell lung cancer (NSCLC). However, epithelial to mesenchymal transition, a widely reported prerequisite for metastasis, may lead to an underestimation of CTC number. We compared directly an epithelial marker-dependent (CellSearch) and a marker-independent (isolation by size of epithelial tumor cells [ISET]) technology platform for the ability to identify CTCs. Molecular characteristics of CTCs were also explored.
Paired peripheral blood samples were collected from 40 chemon?ive, stages IIIA to IV NSCLC patients. CTCs were enumerated by Epithelial Cell Adhesion Molecule-based immunomagnetic capture (CellSearch, Veridex) and by filtration (ISET, RareCell Diagnostics). CTCs isolated by filtration were assessed by immunohistochemistry for epithelial marker expression (cytokeratins, Epithelial Cell Adhesion Molecule, epidermal growth factor receptor) and for proliferation status (Ki67).
CTCs were detected using ISET in 32 of 40 (80%) patients compared with 9 of 40 (23%) patients using CellSearch. A subpopulation of CTCs isolated by ISET did not express epithelial markers. Circulating tumor microemboli (CTM, clusters of ≥ 3 CTCs) were observed in 43% patients using ISET but were undetectable by CellSearch. Up to 62% of single CTCs were positive for the proliferation marker Ki67, whereas cells within CTM were nonproliferative.
Both technology platforms detected NSCLC CTCs. ISET detected higher numbers of CTCs including epithelial marker negative tumor cells. ISET also isolated CTM and permitted molecular characterization. Combined with our previous CellSearch data confirming CTC number as an independent prognostic biomarker for NSCLC, we propose that this complementary dual technology approach to CTC analysis allows more complete exploration of CTCs in patients with NSCLC.
- > 《醫學拾萃》2019年11月刊：靜脈血和末梢血在臨床檢測項目中的差別應用（續）
- > 《醫學拾萃》2019年10月刊：靜脈血和末梢血在臨床檢測項目中的差別應用
- > 《醫學拾萃》2019年9月刊：腎素-血管緊張素-醛固酮系統（RAAS）及其在相關疾病中的調節作用
- > 《醫學拾萃》2019年8月刊：樣本收集和液體活檢對胰腺癌早期診斷的意義
- > 《醫學拾萃》2019年7月刊：全血 RNA 管的應用以及基因表達譜
- > 《醫學拾萃》2019年6月刊：血小板釋放
- > 《醫學拾萃》2019年5月刊：臨檢樣本溶血的原因、鑒定以及對臨檢指標的影響
- > 《醫學拾萃》2019年4月刊：對臨檢樣本分析前誤差的來源和分布的統計
- > 《醫學拾萃》2019年3月刊：巨噬細胞與腫瘤細胞的多重互動及其臨床意義
- > 《醫學拾萃》2019年2月刊：中性粒細胞對腫瘤和循環腫瘤細胞的保護和促進作用